These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30191846)

  • 41. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
    Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
    Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
    [No Abstract]   [Full Text] [Related]  

  • 42. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 43. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 44. Individualized therapy for metastatic colorectal cancer.
    Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
    J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    Sfecci A; Dupuy A; Dinulescu M; Droitcourt C; Adamski H; Hadj-Rabia S; Odent S; Galibert MD; Boussemart L
    J Invest Dermatol; 2017 Apr; 137(4):805-809. PubMed ID: 28340684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [BRAF mutation testing for the choice of melanoma treatment].
    Imianitov EN
    Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Melanoma: from molecular studies to the treatment breakthrough].
    Imianitov EN
    Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Targeted therapy of melanoma: fact or fiction?].
    Svajdler M; Rychlý B; Benický M
    Cesk Patol; 2011 Oct; 47(4):165-7. PubMed ID: 22145215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Up close and personal: the challenges of precision medicine in melanoma.
    Smalley KS; Weber JS
    J Natl Cancer Inst; 2014 Feb; 106(2):djt443. PubMed ID: 24511111
    [No Abstract]   [Full Text] [Related]  

  • 51. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.
    Gangadhar TC; Schuchter LM
    JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246
    [No Abstract]   [Full Text] [Related]  

  • 52. Application of molecular profiling in clinical trials for advanced metastatic cancers.
    Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 54. Two cases of immune thrombocytopenia associated with pembrolizumab.
    Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
    Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
    [No Abstract]   [Full Text] [Related]  

  • 55. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Examination of molecular markers used n the treatment of colon cancer].
    Domagała P; Kowalik A
    Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
    [No Abstract]   [Full Text] [Related]  

  • 57. Methodology of clinical trials in lung cancer.
    Menis J; Besse B; Lacombe D
    Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutation and location important in cancer treatment.
    Lewis R
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
    [No Abstract]   [Full Text] [Related]  

  • 59. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 60. Metastatic colorectal cancer: current state and future directions.
    Fakih MG
    J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.